Engineered immune cells show promise against Hard-to-Treat lymphoma
NCT ID NCT03568461
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a treatment called tisagenlecleucel, a type of CAR-T cell therapy, in 98 adults with follicular lymphoma that had come back or stopped responding to other treatments. The therapy works by reprogramming a patient's own immune cells to find and attack cancer cells. The main goal was to see how many patients had their cancer completely disappear after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope National Medical Center
Duarte, California, 91010 3000, United States
-
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Michigan Med University of Michigan
Ann Arbor, Michigan, 48109 5271, United States
-
Novartis Investigative Site
Camperdown, New South Wales, 2050, Australia
-
Novartis Investigative Site
Melbourne, Victoria, 3000, Australia
-
Novartis Investigative Site
Herston, QLD 4006, Australia
-
Novartis Investigative Site
Linz, 4020, Austria
-
Novartis Investigative Site
Ghent, 9000, Belgium
-
Novartis Investigative Site
Paris, 75475, France
-
Novartis Investigative Site
Pierre-Bénite, 69495, France
-
Novartis Investigative Site
Munich, Bavaria, 81377, Germany
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Ulm, 89081, Germany
-
Novartis Investigative Site
Bologna, BO, 40138, Italy
-
Novartis Investigative Site
Milan, MI, 20132, Italy
-
Novartis Investigative Site
Sapporo, Hokkaido, 060-8648, Japan
-
Novartis Investigative Site
Sendai, Miyagi, 9808574, Japan
-
Novartis Investigative Site
Fukuoka, 8128582, Japan
-
Novartis Investigative Site
Amsterdam, North Holland, 1081 HV, Netherlands
-
Novartis Investigative Site
Oslo, 0310, Norway
-
Novartis Investigative Site
Madrid, 28041, Spain
-
Novartis Investigative Site
Seville, 41013, Spain
-
Novartis Investigative Site
Birmingham, West Midlands, B15 2TH, United Kingdom
-
Novartis Investigative Site
London, SE5 9RS, United Kingdom
-
Oregon Health Sciences University
Portland, Oregon, 97239, United States
-
UCSF Medical Center
San Francisco, California, 94143, United States
-
Uni of Chi Medi Ctr Hema and Onco
Chicago, Illinois, 60637, United States
-
Univ of Kansas Hosp and Med Ctr
Kansas City, Kansas, 66160, United States
-
University of Pennsylvania Clinical
Philadelphia, Pennsylvania, 19104, United States